TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06504459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo LP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05712096

Intervention type: DRUG
Intervention: EVUSHELD
Description: EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
Study: NCT04685135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: 21 day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 21 day cycles
Study: NCT05588388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Addition of Bevacizumab to current standard of care treatment (atezolizumab, carboplatin and etoposide) followed by maintenance Bevacizumab plus Atezolizumab for patients with ES-SCLC with LM
Study: NCT04680715

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Per-Operative Radiotherapy technique by Papillon +TM
Description: 20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer
Study: NCT06363851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kylo-11
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT05409573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double monitoring of EtO2
Description: A double monitoring of EtO2 will be performed during the procedure of intubation (from the beginning of the preoxygenation to the success of intubation):~* In the pharynx (via a nasopharyngeal catheter) for the needs of the study~* On the facemask (as the practice in the OR)
Study: NCT06205602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3BNC117-LS
Description: 30 mg/kg to be administered via IV at Step 1 (Day 1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10-1074-LS
Description: 10 mg/kg to be administered intravenously at Step 1 (Day 1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 3BNC117-LS
Description: 0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 10-1074-LS
Description: 0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
Study: NCT06212453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Microwave Ablation
Description: 3D ultrasound-guided focal thermal ablation of the prostate transition zone
Study: NCT05718570

Intervention type: DRUG
Intervention: Somapacitan
Description: Sogroya therapy in participants with AGHD.
Study: NCT05433961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MagniXene Hyperpolarized Xenon MRI
Description: Magnetic Resonance Imaging of lung function using Hyperpolarized Xenon as a contrast agent.
Study: NCT06585150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeldesivir
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeldesivir Placebo
Description: Tablet administered orally
Study: NCT06585410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered per protocol

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care
Description: Primary surgery
Study: NCT04779320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV
Study: NCT05831579

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton GRID Radiotherapy
Description: The proton GRID radiotherapy prescription dose is 20 Gy x 3 fractions to the tumor, with an integrated dose of 6 Gy x 3 fractions to the PTV. Treatment to multiple lesions within the PTV is allowed (ex. a dominant lesion plus satellites). Multiple proton GRID radiotherapy plans may be delivered on the same day or different days, but they cannot overlap.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton GRID Radiotherapy
Description: The proton GRID radiotherapy prescription dose is 20 Gy x 3 fractions to the tumor, with an integrated dose of 6 Gy x 3 fractions to the PTV. Treatment to multiple lesions within the PTV is allowed (ex. a dominant lesion plus satellites). Multiple proton GRID radiotherapy plans may be delivered on the same day or different days, but they cannot overlap.
Study: NCT04535193

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-mFBG for intravenous administration
Description: Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-mFBG for intravenous administration
Description: Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
Study: NCT04947124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101ophthalmic solution 1%
Description: QLS-101ophthalmic solution 1.0%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101ophthalmic solution 2%
Description: QLS-101ophthalmic solution 2.0%
Study: NCT06073093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT05550532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant
Description: Aticaprant tablet will be administered orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet will be administered orally.
Study: NCT05996406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400mg po qd for 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Dexamethasone 40mg po qw for the first 6 months, then 10mg po qw for the next 6 months
Study: NCT05715229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Immunotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Immunotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Immunotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab
Description: Immunotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Chemotherapy
Study: NCT06110273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit for Duty-mobile
Description: Fit for Duty-mobile participants will receive self-regulatory support and behavior change techniques via an initial core intervention delivered through a native smartphone app (includes connected device data, 10 weekly lessons, weekly tailored feedback) and 4 coaching calls (weeks 1, 4, 8, and 16). App based tailored feedback and messaging will continue through 2 years. Optional 4-week refresher e-campaigns are offered every 6 mos. after the initial core intervention. Participants choose to follow either a Small Changes approach or a Large Changes approach and may choose to switch approaches over the 2 years, if desired.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: m-Health Control
Description: Participants receive digital tools and education on weight gain prevention behaviors at baseline.
Study: NCT06220851

Intervention type: DIAGNOSTIC_TEST
Intervention: Handgrip strength
Description: Handgrip strength will be measured by 3 efforts.
Study: NCT05536804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06576843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-6001
Description: Extended-release subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-6001
Description: Extended-release subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-6001
Description: Extended-release subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-6001
Description: Extended-release subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-6001
Description: Extended-release subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-6001
Description: Extended-release subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: Oral sublingual film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: Oral sublingual film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: Oral sublingual film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: Oral sublingual film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublocade
Description: Extended-release subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublocade
Description: Extended-release subcutaneous injection
Study: NCT04979416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video messages
Description: video messages aimed at increasing vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video messages
Description: video messages aimed at increasing vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video messages
Description: video messages aimed at increasing vaccination
Study: NCT04356287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSC
Description: Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSC
Description: Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each infusion will consist of 50 mL of PlasmaLyte A.
Study: NCT05207527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiovascular exercise
Description: Exercise that mainly stimulates the cardiovascular and respiratory systems.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiovascular exercise
Description: Exercise that mainly stimulates the cardiovascular and respiratory systems.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strength
Description: Exercise that primarily stimulates the musculoskeletal system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strength
Description: Exercise that primarily stimulates the musculoskeletal system.
Study: NCT06578247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Participants will receive quizartinib at 60 mg/day orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Participants will receive quizartinib at 60 mg/day orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo at 60 mg/day orally once daily
Study: NCT05207527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed
Description: Exercise that stimulates the musculoskeletal, cardiovascular and respiratory systems.
Study: NCT06578247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo at 60 mg/day orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
Study: NCT06048393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA55 nasal spray
Description: The novel coronavirus broad-spectrum neutralizing antibody SA55 nasal spray (SA55 nasal spray) is provided by Beijing Kexing Zhongwei Biotechnology Co., Ltd. The main component of this product is the novel coronavirus broad-spectrum neutralizing antibody, which is a colorless to pale yellow solution. Each milliliter contains 5mg of broad-spectrum neutralizing antibody against novel coronavirus. Excipients include histidine hydrochloride, arginine hydrochloride, histidine, sucrose, polysorbate 80 (II), hydroxypropyl cellulose, glycerol, and benzalkonium chloride (concentration 0.005%).~20 sprays per bottle, approximately 100 sprays per bottle μ L. Containing 0.5 mg of broad-spectrum neutralizing antibody against novel coronavirus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SA55 nasal spray
Description: The novel coronavirus broad-spectrum neutralizing antibody SA55 nasal spray (SA55 nasal spray) is provided by Beijing Kexing Zhongwei Biotechnology Co., Ltd. The main component of this product is the novel coronavirus broad-spectrum neutralizing antibody, which is a colorless to pale yellow solution. Each milliliter contains 5mg of broad-spectrum neutralizing antibody against novel coronavirus. Excipients include histidine hydrochloride, arginine hydrochloride, histidine, sucrose, polysorbate 80 (II), hydroxypropyl cellulose, glycerol, and benzalkonium chloride (concentration 0.005%).~20 sprays per bottle, approximately 100 sprays per bottle μ L. Containing 0.5 mg of broad-spectrum neutralizing antibody against novel coronavirus.
Study: NCT06578247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
Study: NCT06119685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-023
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-023
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-023
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-023
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-023
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-023
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Anti-CD20 antibody therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Anti-CD38 antibody therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy
Study: NCT06015048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 combined with Pyrotinib.
Description: SHR-A1811 combined with Pyrotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 combined with other antitumor therapies
Description: SHR-A1811 combined with other antitumor therapies
Study: NCT05782790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation Theraphy Group
Description: In this method, patients will be seated in a comfortable chair in front of a 32-inch television placed approximately 2 meters away in a quiet room. On television, videos that will be used in swallowing rehabilitation prepared on realistic animations and/or real models will be shown to the patients. Patients will be asked to watch these exercise videos for 20 minutes with their full attention and concentrate on how the actions are done.~Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classic Swallowing Exercise Group
Description: Exercises include positioning, swallowing maneuvers, food modification, and swallowing exercises, which are sensory stimulation, oral motor exercises, head-neck mobilization, Shaker exercises, and neck region and tongue strengthening exercises, which are compensatory strategies according to the swallowing rehabilitation program accepted in the literature. Evaluations to be made before starting the treatment program and finished; demographic information, Standardized Mini Mental Test, Turkish Eating Assessment Tool, Videofluoroscopic Swallowing Study (VFYC), Penetration Aspiration Scale (PAS), Evaluation of Swallowing Ability and Function, Surface Electromyographic Measurements of Suprahyoid Muscles, Swallowing Quality of Life Questionnaire, Beck Depression Scale.
Study: NCT06206395

Intervention type: DEVICE
Intervention: Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging
Description: 2D speckle tracking echo will be performed before chemotherapy and after mid-cycle and after completion of treatment.~3D echo and CMR will be performed before and after chemotherapy treatment.
Study: NCT04782726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Software Solution for Radiation Therapy Treatment
Description: Software has been developed for individualized pre optimization evaluation of the patient anatomy and prescribed dose of radiation therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiation therapy
Description: Standard of Care planning for Radiation therapy is used to treat the subjects for head and neck cancer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Standard of Care planning for Radiation therapy is used to treat the subjects for head and neck cancer
Study: NCT05589675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dispatch of the screening test along the invitation letter to the national colorectal cancer screening program
Description: The individuals eligible for the colorectal cancer screening program will receive at home an invitation letter to participate to the program along with a FIT test. The follow-up will be similar to the standard of care, i.e. reminder letters at 5 and 10 months if there is no participation, and reminders if no coloscopy after a positive FIT test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dispatch of the screening test along the invitation letter to the national colorectal cancer screening program
Description: The individuals eligible for the colorectal cancer screening program will receive at home an invitation letter to participate to the program along with a FIT test. The follow-up will be similar to the standard of care, i.e. reminder letters at 5 and 10 months if there is no participation, and reminders if no coloscopy after a positive FIT test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sending of a prior notification to the new entrants of the national program
Description: Dispatch of a notification, one month prior the dispatch of the screening test along the invitation letter. This intervention is among the new entrants to the national program
Study: NCT06098846

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D phosphate
Description: Application of a Vitamin D phosphate active patch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D phosphate
Description: Application of a Vitamin D phosphate active patch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D phosphate
Description: Application of a Vitamin D phosphate active patch

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch
Description: Application of a placebo transdermal patch
Study: NCT05635149

Intervention type: RADIATION
Intervention: radiotherapy
Description: In radiotherapy group, the modality of radiotherapy was conventional radiotherapy (CRT) or stereotactic body radiotherapy (SBRT) for cancer.